Topoisomerase i targeting agents in small-cell lung cancer

Current Oncology Reports

Volumn 3, Issue 2, 2001, Pages 170-178

  Ohe, Yuichiro ^a   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

CDDP; Etoposide; Irinotecan; Small Cell Lung Cancer; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; IRINOTECAN;

ADJUVANT THERAPY; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; LUNG TUMOR; METABOLISM; MULTIMODALITY CANCER THERAPY; REVIEW; SMALL CELL CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; DNA TOPOISOMERASES, TYPE I; HUMANS; LUNG NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 0035293633     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-001-0018-3     Document Type: Article

References (50)

1. Turrisi A, Kim K, Blum R, et al.: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999, 340:265–271. DOI: 10.1056/NEJM199901283400403
2. Fukuoka M, Furuse K, Saijo N, et al.: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991, 83:855–861. DOI: 10.1093/jnci/83.12.855
3. Greco FA, Richardson RL, Snell JD, et al.: Small cell lung cancer: complete remission and improved survival. Am J Med 1979, 66:625–630. DOI: 10.1016/0002-9343(79)91173-2
4. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al.: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993, 85:271–291. DOI: 10.1093/jnci/85.4.271
5. Creemerst GJ, Lund B, Verweij J: Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994, 20:73–96. DOI: 10.1016/0305-7372(94)90011-6
6. Dancey J, Eisenhauer EA: Current perspectives on camptothecins in cancer treatment. Br J Cancer 1996, 74:327–338.
7. Kaneda N, Nagata H, Furuta T, et al.: Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990, 50:1715–1720.
8. Kawato Y, Aonuma M, Hirota Y, et al.: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, the antitumor effect of CPT-11. Cancer Res 1991, 51:4187–4191.
9. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041–1047. DOI: 10.1016/S0140-6736(00)02034-1
10. Cunningham D, Pyrhonen S, James RD, et al.: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413–1418. DOI: 10.1016/S0140-6736(98)02309-5
11. Rougier P, Van Cutsem E, Bajetta E: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407–1412. DOI: 10.1016/S0140-6736(98)03085-2
12. Noda K, Nishiwaki Y, Kawahara M, et al.: Randomized phase III study of irinotecan (CPT-11) and cisplatin versus etoposide and cisplatin in extensive-disease small-cell lung cancer: Japan Clinical Oncology Group study (JCOG9511) [abstract]. Proc ASCO 2000, 19:483a. This phase III study demonstrated that treatment with four cycles of irinotecan plus cisplatin every 4 weeks yielded a highly significant improvement in survival over standard etoposide plus cisplatin, with less myelosuppression, in patients with extensive-disease small-cell lung cancer.
13. Yoshinari T, Matsumoto M, Arakawa H, et al.: Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res 1995, 55:1310–1315.
14. Arakawa H, Iguchi T, Morita M, et al.: Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4c]carbazole-5,7(6H)-dione (NB-506): its potent antitumor activities in mice. Cancer Res 1995, 55:1316–1320.
15. Ohe Y, Tanigawara Y, Fujii H, et al.: Phase I and pharmacology study of 5-day infusion of NB-506 [abstract]. Proc ASCO 1997, 16:199a.
16. Arakawa H, Morita M, Kodera T, et al.: In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice. Jpn J Cancer Res 1999, 90:1163–1170.
17. Yoshinari T, Ohkubo M, Fukasawa K, et al.: Mode of action of new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res 1999, 59:4271–4275.
18. Negoro S, Fukuoka M, Masuda N, et al.: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991, 83:1164–1168. DOI: 10.1093/jnci/83.16.1164
19. Ohe Y, Sasaki Y, Shinkai T, et al.: Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 1992, 84:972–974. DOI: 10.1093/jnci/84.12.972
20. Abigerges D, Chabot GG, Armand JP, et al.: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995, 13:210–221.
21. Rothenberg ML, Kuhn JG, Burris HA, et al.: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993, 11:2194–2204.
22. DeVore RF, Blanke CD, Denharm CA, et al.: Phase II study of irinotecan (CPT-11) in patients with previously treated small-cell lung cancer (SCLC) [abstract]. Proc ASCO 1998, 17:451a.
23. Rowinsky EK, Grochow LB, Hendricks CB, et al.: Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992, 10:647–656.
24. Eckardt J, Palmer MC, Fanucchi M, et al.: Oral topotecan (OT) as single-agent first-line treatment for patients with extensive disease (ED) small cell lung cancer (SCLC) ineligible for standard therapy: a phase II study [abstract]. Proc ASCO 2000, 19:494a.
25. Eckhardt SG, Baker SD, Eckardt JR, et al.: Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. Clin Cancer Res 1998, 4:595–604.
26. Gerrits CJ, Creemers GJ, Schellens JH, et al.: Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. Br J Cancer 1996, 73:744–750.
27. Sessa C, Wanders J, Roelvink M, et al.: Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG). Ann Oncol 2000, 11:207–210. The EORTC demonstrated activity with the new topoisomerase I inhibitor GG211 as a second-line treatment of SCLC. DOI: 10.1023/A:1008372404504
28. Negoro S, Fukuoka M, Niitani H, et al.: Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC) [abstract]. Proc ASCO 1991, 10:241.
29. Masuda N, Fukuoka M, Kusunoki Y, et al.: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992, 10:1225–1229.
30. Schiller JH, Kim K, Hutson P, et al.: Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1996, 14:2345–2352.
31. Perez-Soler R, Glisson BS, Lee JS, et al.: Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996, 14:2785–2790.
32. Ardizzoni A, Hansen H, Dombernowsky P, et al.: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997, 15:2090–2096.
33. Kudoh S, Takada M, Masuda N, et al.: Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 1993, 84:203–207.
34. Kudoh S, Fujiwara Y, Takada Y, et al.: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 1998, 16:1068–1074. Report of very encouraging results with irinotecan plus cisplatin, especially for patients with ED-SCLC. Based on this study, the JCOG conducted a phase III study of cisplatin plus irinotecan versus cisplatin plus etoposide for untreated ED-SCLC (JCOG9511).
35. Kim R, Hirabayashi N, Nishiyama M, et al.: Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 1992, 50:760–766. DOI: 10.1002/ijc.2910500516
36. Masuda N, Matsui K, Negoro S, et al.: Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1998, 16:3329–3334. In a study of combination chemotherapy with irinotecan and etoposide for refractory and relapsed SCLC, a 71% overall response rate and 271-day MST were reported.
37. Nakamura S, Kudoh S, Komuta K, et al.: Phase II study of irinotecan (CPT-11) combined with etoposide (VP-16) for previously untreated extensive-disease small cell lung cancer (ED-SCLC): a study of the West Japan Lung Cancer Group [abstract]. Proc ASCO 1999, 18:470a.
38. Ardizzoni A, Manegold C, Gaafar R, et al.: Combination chemotherapy with cisplatin and topotecan as second-line treatment of sensitive (S) and refractory (R) small cell lung cancer (SCLC): an EORTC LCCG phase II study [abstract]. Proc ASCO 1999, 18:471a.
39. Miller AA, Lilenbaum RC, Lynch TJ, et al.: Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol 1996, 14:1964–1965.
40. Lynch T, Herndon J, Lyss A, et al.: Paclitaxel (P) + topotecan (T) + GCSF for previously untreated extensive small cell lung cancer (E-SCLC): preliminary analysis of Cancer and Leukemia Group B (CALGB) 9430 [abstract]. Proc ASCO 2000, 19:491a.
41. Gray J, Hainsworth J, Burris H, et al.: Paclitaxel, carboplatin, and topotecan in the treatment of small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network [abstract]. Proc ASCO 2000, 19:494a.
42. Jett J, Hatfield A, Bauman M, et al.: Phase II trial of topotecan and paclitaxel (TP) with G-CSF support alternating with etoposide and cisplatin (EC) in previously untreated extensive stage small cell lung cancer (ED-SCLC) [abstract]. Proc ASCO 2000, 19:491a.
43. Panza N, Frasci G, Comella P, et al.: Weekly cisplatin-paclitaxeltopotecan (CPT) as front-line therapy for extensive disease small cell lung cancer (ED-SCLC): a Southern Italy Cooperative Oncology Group (SICOG) phase II study [abstract]. Proc ASCO 2000, 19:492a.
44. von Pawel J, Schiller JH, Shepherd FA, et al.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658–667. This phase III study demonstrated that topotecan is at least as effective as CAV in the treatment of patients with recurrent SCLC, and results in improved control of several symptoms.
45. Johnson D, Adak S, Cella D, et al.: Topotecan (T) vs. observation (OB) following cisplatin (P) plus etoposide (E) in extensive stage small cell lung cancer (ES SCLC) (E7593): a phase III trial of the Eastern Cooperative Oncology Group (ECOG) [abstract]. Proc ASCO 2000, 19:482a.
46. Yokoyama A, Kurita Y, Saijo N, et al.: Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer. Br J Cancer 1998, 78:257–262. DOI: 10.1038/bjc.1998.474
47. Saka H, Shimokata K, Yoshida S, et al.: Irinotecan (CPT-11) and concurrent radiotherapy in locally advanced non-small cell lung cancer (NSCLC): a phase II study of Japan Clinical Oncology Group (JCOG9504) [abstract]. Proc ASCO 1997, 16:447a.
48. Morisada S, Yanagi Y, Noguchi T, et al.: Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 1989, 80:69–76.
49. Ohe Y, Nakagawa K, Fujiwara Y, et al.: In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Cancer Res 1989, 49:4098–4102.
50. Yana T, Negoro S, Takada Y, et al.: Phase II study of amrubicin (SM-5887), a 9-amino-anthracycline, in previously untreated patients with extensive stage small-cell lung cancer (ES-SCLC): a West Japan Lung Cancer Group trial [abstract]. Proc ASCO 1998, 17:450a.